- Home
- Publications
- Publication Search
- Publication Details
Title
Genetic and Epigenetic Complexity in Myeloproliferative Neoplasms
Authors
Keywords
-
Journal
Hematology-American Society of Hematology Education Program
Volume 2011, Issue 1, Pages 208-214
Publisher
American Society of Hematology
Online
2011-12-08
DOI
10.1182/asheducation-2011.1.208
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis
- (2011) J. H. Smalberg et al. BLOOD
- Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival
- (2011) R. Vaidya et al. BLOOD
- JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation
- (2011) Fan Liu et al. CANCER CELL
- MPL Mutation Profile in JAK2 Mutation-negative Patients With Myeloproliferative Disorders
- (2011) Wanlong Ma et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues
- (2011) R. A. Van Etten et al. HAEMATOLOGICA
- Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera
- (2011) S. I. Swierczek et al. HAEMATOLOGICA
- DNMT3A mutations in myeloproliferative neoplasms
- (2011) F Stegelmann et al. LEUKEMIA
- DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms
- (2011) O Abdel-Wahab et al. LEUKEMIA
- Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation
- (2011) Gabriella Ficz et al. NATURE
- The Constitutive Activation of Jak2-V617F Is Mediated by a π Stacking Mechanism Involving Phenylalanines 595 and 617
- (2010) Kavitha Gnanasambandan et al. BIOCHEMISTRY
- The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms
- (2010) A. V. Jones et al. BLOOD
- Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms
- (2010) F. X. Schaub et al. BLOOD
- Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
- (2010) S. T. Oh et al. BLOOD
- Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms
- (2010) F. Baran-Marszak et al. BLOOD
- Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 Signaling
- (2010) Edwin Chen et al. CANCER CELL
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
- (2010) Maria E. Figueroa et al. CANCER CELL
- The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms
- (2010) D. Olcaydu et al. HAEMATOLOGICA
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis
- (2010) P Guglielmelli et al. LEUKEMIA
- IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
- (2010) A Tefferi et al. LEUKEMIA
- LNK mutation studies in blast-phase myeloproliferative neoplasms and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
- (2010) A Pardanani et al. LEUKEMIA
- Deletions of the transcription factor Ikaros in myeloproliferative neoplasms
- (2010) R Jäger et al. LEUKEMIA
- Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
- (2010) Myunggon Ko et al. NATURE
- Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia
- (2010) Charlotte M Niemeyer et al. NATURE GENETICS
- Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
- (2010) Thomas Ernst et al. NATURE GENETICS
- L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability
- (2010) N. Gurvich et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- JAK2V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms
- (2010) Stephen T Oh et al. Expert Review of Hematology
- Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
- (2009) F. H. Grand et al. BLOOD
- Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones
- (2009) Philip A. Beer et al. BRITISH JOURNAL OF HAEMATOLOGY
- Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis
- (2009) L. Teofili et al. HAEMATOLOGICA
- The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera
- (2009) D Olcaydu et al. LEUKEMIA
- JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
- (2009) A Tefferi et al. LEUKEMIA
- Mutations of ASXL1 gene in myeloproliferative neoplasms
- (2009) N Carbuccia et al. LEUKEMIA
- TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
- (2009) A Tefferi et al. LEUKEMIA
- JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
- (2009) Mark A. Dawson et al. NATURE
- Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms
- (2009) Masashi Sanada et al. NATURE
- A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms
- (2009) Damla Olcaydu et al. NATURE GENETICS
- A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms
- (2009) Outi Kilpivaara et al. NATURE GENETICS
- JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
- (2009) Amy V Jones et al. NATURE GENETICS
- Mutation inTET2in Myeloid Cancers
- (2009) François Delhommeau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations
- (2008) S. Li et al. BLOOD
- Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F
- (2008) F. X. Schaub et al. BLOOD
- Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden
- (2008) O. Landgren et al. BLOOD
- JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
- (2008) I. Plo et al. BLOOD
- Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders
- (2008) Daniela Capello et al. BRITISH JOURNAL OF HAEMATOLOGY
- Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders
- (2008) N. Fourouclas et al. HAEMATOLOGICA
- Substitution of Pseudokinase Domain Residue Val-617 by Large Non-polar Amino Acids Causes Activation of JAK2
- (2008) Alexandra Dusa et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started